We previously analyzed a model of FGFR3 mutation in bladder cancer, considering the therapeutic efficacy of combination ICI and a small molecule inhibitor (SMI) of FGFR3 (18). This evidence concerns the gene FGFR3 and urinary bladder carcinoma.